{"organizations": [], "uuid": "82344e6b35737e5369d6da39deb72c428a83a1db", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000551/device/rss", "section_title": "California", "url": "https://www.cnbc.com/2018/02/22/the-associated-press-biomarin-reports-4q-loss.html", "country": "US", "domain_rank": 767, "title": "BioMarin reports 4Q loss", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-22T23:31:00.000+02:00", "replies_count": 0, "uuid": "82344e6b35737e5369d6da39deb72c428a83a1db"}, "author": "cnbc.com", "url": "https://www.cnbc.com/2018/02/22/the-associated-press-biomarin-reports-4q-loss.html", "ord_in_thread": 0, "title": "BioMarin reports 4Q loss", "locations": [], "entities": {"persons": [], "locations": [{"name": "san rafael", "sentiment": "none"}, {"name": "calif.", "sentiment": "none"}, {"name": "san rafael", "sentiment": "none"}], "organizations": [{"name": "biomarin", "sentiment": "negative"}, {"name": "biomarin pharmaceutical inc.", "sentiment": "negative"}, {"name": "ap", "sentiment": "negative"}, {"name": "zacks investment research", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "SAN RAFAEL, Calif. (AP) _ BioMarin Pharmaceutical Inc. (BMRN) on Thursday reported a loss of $51.4 million in its fourth quarter.\nThe San Rafael, California-based company said it had a loss of 30 cents per share.\nThe results missed Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was for a loss of 24 cents per share.\nThe rare disease biopharmaceutical posted revenue of $358.3 million in the period, which topped Street forecasts. Ten analysts surveyed by Zacks expected $346.2 million.\nFor the year, the company reported that its loss narrowed to $117 million, or 67 cents per share. Revenue was reported as $1.31 billion.\nBioMarin expects full-year revenue in the range of $1.47 billion to $1.53 billion.\nBioMarin shares have dropped roughly 6 percent since the beginning of the year. In the final minutes of trading on Thursday, shares hit $84, a drop of slightly more than 6 percent in the last 12 months.\nThis story was generated by Automated Insights ( http://automatedinsights.com/ap ) using data from Zacks Investment Research. Access a Zacks stock report on BMRN at https://www.zacks.com/ap/BMRN", "external_links": [], "published": "2018-02-22T23:31:00.000+02:00", "crawled": "2018-02-23T01:05:15.008+02:00", "highlightTitle": ""}